Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020

References

• Grammatikos AP, Mantadakis E, Falagas ME. Meta-analyses on pediatric infections and vaccines. Infect Dis Clin North Am. 2009;23:431–57. doi:10.1016/j.idc.2009.01.008.
   PubMed Web of Science ®Google Scholar
• Ahmad SR. Adverse drug event monitoring at the food and drug administration. J Gen Intern Med. 2003;18:57–60. doi:10.1046/j.1525-1497.2003.20130.x.
   PubMed Web of Science ®Google Scholar
• De St Maurice A, Edwards KM. Post-licensure monitoring to evaluate vaccine safety. J Pediatr. 2015;166:513–15. doi:10.1016/j.jpeds.2014.12.031.
   PubMed Web of Science ®Google Scholar
• Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750–57. doi:10.1001/jama.2009.1201.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson S-E, Høye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459–66. doi:10.1038/sj.bjc.6603469.
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil): profile report. BioDrugs. 2006;20:313–16. doi:10.2165/00063030-200620050-00006.
   PubMed Web of Science ®Google Scholar
• Vaccine package insert for human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). [accessed 2021 June 15]. https://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf.
   Google Scholar
• Meeting of the WHO human papillomavirus vaccine advisory committee, April 2010. Releve epidemiologique hebdomadaire / Section d’hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations. 2011;86:227–31.
   PubMedGoogle Scholar
• Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE, Shimabukuro TT. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the vaccine adverse event reporting system (VAERS), 2009–2015. Vaccine. 2018;36:1781–88. doi:10.1016/j.vaccine.2018.02.034.
   PubMed Web of Science ®Google Scholar
• Sy LS, Meyer KI, Klein NP, Chao C, Velicer C, Cheetham TC, Ackerson BK, Slezak JM, Takhar HS, Hansen J, et al. Postlicensure safety surveillance of congenital anomaly and miscarriage among pregnancies exposed to quadrivalent human papillomavirus vaccine. Hum Vaccin Immunother. 2018;14:412–19. doi:10.1080/21645515.2017.1403702.
   PubMed Web of Science ®Google Scholar
• Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the vaccine safety datalink. Vaccine. 2011;29(46):8279–84. doi:10.1016/j.vaccine.2011.08.106.
   PubMed Web of Science ®Google Scholar
• Ward D, Thorsen NM, Frisch M, Valentiner-Branth P, Molbak K, Hviid A. A cluster analysis of serious adverse event reports after human papillomavirus (HPV) vaccination in Danish girls and young women, September 2009 to August 2017. Euro Surveillance. 2019;24:1800380.
   PubMedGoogle Scholar
• Hviid A, Svanstrom H, Scheller NM, Gronlund O, Pasternak B, Arnheim-Dahlstrom L. Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. J Intern Med. 2018;283:154–65. doi:10.1111/joim.12694.
   PubMed Web of Science ®Google Scholar
• Liu D, Wu W, Li K, Xu D, Ye J, Li L, Wang H. Surveillance of adverse events following immunization in China: past, present, and future. Vaccine. 2015;33:4041–46. doi:10.1016/j.vaccine.2015.04.060.
   PubMed Web of Science ®Google Scholar
• Rust J. Updating the international classification of diseases and related health problems, tenth revision (ICD-10). Health Inf Manag. 2010;39:40. doi:10.1177/183335831003900207.
   PubMedGoogle Scholar
• Li Q, Hu Y, Zhong Y, Chen Y, Tang X, Guo J, Shen L. Using the immunization information system to determine vaccination coverage rates among children aged 1–7 years: a report from Zhejiang Province, China. Int J Environ Res Public Health 2014; 11:2713–28.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li Q, Lin L, Chen E, Chen Y, Qi X. Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China. Clin Vaccine Immunol. 2013;20:211–17. doi:10.1128/CVI.00541-12.
   PubMed Web of Science ®Google Scholar
• Kim S, Park K, Kim MS, Yang BR, Choi HJ, Park BJ. Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database. Psychiatry Res. 2017;256:237–42. doi:10.1016/j.psychres.2017.06.038.
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796–803. doi:10.7150/ijms.6048.
   PubMed Web of Science ®Google Scholar
• Clothier HJ, Lawrie J, Lewis G, Russell M, Crawford NW, Buttery JP. SAEFVIC: surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018. Commun Dis Intell. 2018;2020:44.
   Google Scholar
• Joshi J, Das MK, Polpakara D, Aneja S, Agarwal M, Arora NK. Vaccine safety and surveillance for adverse events following immunization (AEFI) in India. Indian J Pediatr. 2018;85:139–48. doi:10.1007/s12098-017-2532-9.
   PubMed Web of Science ®Google Scholar
• Schumacher Z, Bourquin C, Heininger U. Surveillance for adverse events following immunization (AEFI) in Switzerland–1991–2001. Vaccine. 2010;28:4059–64. doi:10.1016/j.vaccine.2010.04.002.
   PubMed Web of Science ®Google Scholar
• Hibbs BF, Moro PL, Lewis P, Miller ER, Shimabukuro TT. Vaccination errors reported to the vaccine adverse event reporting system, (VAERS) United States, 2000–2013. Vaccine. 2015;33:3171–78. doi:10.1016/j.vaccine.2015.05.006.
   PubMed Web of Science ®Google Scholar
• Gee J, Sukumaran L, Weintraub E, Vaccine Safety Datalink T. Risk of guillain-barre syndrome following quadrivalent human papillomavirus vaccine in the vaccine safety datalink. Vaccine. 2017;35:5756–58. doi:10.1016/j.vaccine.2017.09.009.
   PubMed Web of Science ®Google Scholar
• Ojha RP, Jackson BE, Tota JE, Offutt-Powell TN, Singh KP, Bae S. Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. Hum Vaccin Immunother. 2014;10:232–37. doi:10.4161/hv.26292.
   PubMed Web of Science ®Google Scholar
• Neha R, Subeesh V, Beulah E, Gouri N, Maheswari E. Postlicensure surveillance of human papillomavirus vaccine using the vaccine adverse event reporting system, 2006–2017. Perspect Clin Res. 2020;11:24–30. doi:10.4103/picr.PICR_140_18.
   PubMedGoogle Scholar
• Munoz N, Manalastas R Jr., Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373:1949–57. doi:10.1016/S0140-6736(09)60691-7.
   PubMed Web of Science ®Google Scholar
• Jens U, Michael S, Jos´e MB, Michael D, Jan B, Sheila F, Glacus S, Ulrich H, Babatunde I, Ali K, et al. Anaphylaxis: Case Definition and Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data. Vaccine. 2007;25:5675–84.
   PubMed Web of Science ®Google Scholar